Monoclonal antibody Bebtelovimab neutralizes all isoforms of Omicron variants
- The new coronavirus may kill cancer cells and achieve a permanent cure!
- Why did the Alzheimer’s drug candidate BACE1 inhibitor fail?
- LRTI Death: Research spanning 80 years confirms for the first time
- The decline of the global antibiotic market is threatening the development of new drugs
- World first: An mRNA vaccine that can 100% protect against deadly bacterial infections is available
- The first successful use of CAR-T cells to treat severe muscle inflammation
Monoclonal antibody Bebtelovimab neutralizes all isoforms of Omicron variants
- More than 1 million Chinese died after China quit “Zero-COVID policy”?
- Why is Vinyl chloride listed as a Class A “known human carcinogen” ?
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
Monoclonal antibody Bebtelovimab neutralizes all isoforms of Omicron variants.
Recently, a research paper on “Antibody evasion properties of SARS-CoV-2 Omicron sublineages” was published in “Nature”.
After experimenting with 19 monoclonal antibodies, the study found that only the bebtelovimab ( LY-COV1404 ) antibody can adequately neutralize all subtypes of the omicron variant .
These findings are part of a recent analysis by the team that showed that the three subtypes of Omicron mutated to the same extent as wild-type SARS-CoV-2 (SARS-CoV-2) and reduced the risk of mRNA vaccines Similar comparability in potency .
After confirming the Omicron BA.1 mutant, the authors continued to monitor two clades where further variants were found: BA.1+ R346K and BA.2 .
The BA.1 + R346K subtype accounts for about 40% of the present global Omicron sequences and 35-60% in New Zealand, the UK and the US.
The BA.2 subtype, which accounts for about 10% of the global Omicron sequence, is increasing in prevalence and has become predominant in Denmark, India, and South Africa.
In addition, the authors investigated the sensitivity of each subtype of Omicron to neutralizing sera from individuals previously infected with wild-type 2019-nCoV (10 individuals), vaccinated with Pfizer-BioNTech (13 individuals), or Modder NA (12 people) vaccine individuals, and individuals who received any of the above mRNA vaccines as booster shots (15 people).
The authors found that the neutralizing activity of serum for BA.1 + R346K and BA.2 subtypes was significantly lower than that of wild-type 2019-nCoV, and the degree of decline was comparable to that of BA.1 previously reported.
However, the reduction in neutralizing activity was less pronounced in the sera of booster-vaccinated individuals.
(Figure 1. BA.2 shows a serum neutralization profile similar to the BA.1 subtype.)
In laboratory experiments against 19 monoclonal antibodies, the authors found that BA.2 was significantly resistant to 17 of them. This includes a 27-fold decrease in the activity of sotrovimab, which retains decent activity against both BA.1 and BA.1 + R246K. Of the other two antibodies, cilgavimab (alone or in combination with tixagevimab) retained activity against BA.2 but was ineffective against BA.1. Only the recently approved bebtelovimab is effective against all three subtypes of Omicron.
(Figure 2. BA.2 has different resistance to monoclonal antibodies)
The team concluded in the paper that the emergence of new coronavirus variants has reduced treatment options, and new strategies must continue to be developed to control the new coronavirus.
Monoclonal antibody Bebtelovimab neutralizes all isoforms of Omicron variants
(source:internet, reference only)
Disclaimer of medicaltrend.org
